Draft Biosimilar Red Tape Elimination Act: Pharmacist As Ally, Would Patients Benefit?

What's The Generics Experience?

If the bill on the Biosimilar Red Tape Elimination Act is passed, all biosimilars would be deemed interchangeable on US FDA approval. Scrip takes a look at what empowering pharmacists could mean, what the generics substitution experience shows and where possible pain points lie

US Healthcare System Savings
If Enacted, The Biosimilars Red Tape Elimination Act Could Have A Far-Reaching Impact • Source: Shutterstock

The bill on the Biosimilar Red Tape Elimination Act reintroduced by Senator Mike Lee, backed by senators Ben Ray Lujan, Mike Braun and J.D. Vance, could have a significant impact if it becomes an Act.

Intending to amend existing legislation to state that all biosimilars, upon approval by the US Food and Drug Administration (FDA),...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.